Neumora Therapeutics Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 NEUMORA THERAPEUTICS, INC. Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file suchreports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growthcompany☐ Accelerated filer☐Smaller reportingcompany☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d)of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.Yes☐No☒ As of August 10, 2026, the registrant had 187,895,912 shares of common stock, $0.0001 par value per share, outstanding. Special Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q contains forward-looking statements concerning our business, operations andfinancial performance and condition, as well as our plans, objectives and expectations for our business, operationsand financial performance and condition. Any statements contained herein that are not statements of historical factsmay be deemed to be forward-looking statements. These statements involve known and unknown risks, uncertaintiesand other important factors that are in some cases beyond our control and may cause our actual results, performanceor achievements to be materially different from any future results, performance or achievements expressed orimplied by the forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,”“believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,”“plan,”“predict,”“potential,”“positioned,”“seek,”“should,”“target,”“will,”“would,”and other similarexpressions that are predictions of or indicate future events and future trends, or the negative of these terms or othercomparable terminology. These forward-looking statements include, but are not limited to, statements about: i•our expectations regarding the potential market size and size of the potential patient populations for ourproduct candidates and any future product candidates, if approved for commercial use;•our clinical and regulatory development plans including any related anticipated program milestones;•the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and otherpositive results;•our expectations with regard to the results of our clinical studies, preclinical studies and research anddevelopment programs, including the timing and availability of data from such studies;•our estimates of the number of patients that we will enroll in our clinical trials and the timing of theirenrollment;•thetiming of commencement of future preclinical studies and clinical trials and research anddevelopment programs;•our ability to acquire, discover, develop and advance product candidates into, and successfullycomplete, clinical trials;•our ability to reduce the time or increase the likelihood of success of our research and developmentrelative to the traditional drug discovery paradigm using our precision neuroscience approach;•our ability to improve, and the rate of improvement in, our precision neuroscience approach, or torealize benefits from such improvements;•our expectations related to our precision neuroscience approach, including but not limited to whether itwill have the same impact as data-driven precision medicine in the oncology field;•our ability to achieve our mission to redefine neuroscience drug development by bringing forward thenext generation of novel t